Today, anti-VEGF agents are commonly used as the first-line therapy for macular edema caused by retinal diseases such as age-related macular degeneration, retinal vein occlusion, certain retinal tumors and diabetic retinopathy [17–20]. The gene discussed is VEGFA; the disease is retina neoplasm.